Recent developments highlight Neuraxis’ record Q2 2026 results driven by PENFS growth, expanded insurance coverage for IB-Stim therapy, inclusion of PENFS technology in pediatric gastroenterology guidelines, and significant stock gains reflecting market interest.

• Neuraxis posted record Q2 2026 results driven by growth in PENFS therapy adoption [N6].
• The company expanded PENFS insurance coverage by 18 million lives, enhancing patient access to IB-Stim therapy [N2].
• PENFS technology was included in pediatric gastroenterology guidelines as the only FDA-cleared treatment recommended [N2].
• Neuraxis stock gained significantly post Q1 and Q4 earnings reports, reflecting revenue and margin improvements year-over-year [N7].
• The company completed a $5 million registered direct offering in May 2025 to support growth of IB-Stim therapy [N2].
• Neuraxis terminated the NSS-2 Bridge license with Masimo in July 2025, regaining rights to related trademarks and patents [S1].
• Despite revenue surges and gross margin improvements, the stock dipped post Q2 2026 earnings, indicating market sensitivity to other factors [N4].

Neuraxis benefits from strong clinical evidence and regulatory endorsements positioning IB-Stim as the only FDA-cleared and guideline-recommended treatment for pediatric functional abdominal pain. The company’s expanding insurance coverage and Federal Supply Schedule contract enhance patient access. Ongoing clinical trials for additional indications could broaden the product’s market potential. The direct sales force and established presence in approximately 80 children’s hospitals support commercial execution. Recent record quarterly results and revenue growth reflect adoption momentum [N2][N6][N7].

The company operates in a competitive neurostimulation market with larger, established players possessing greater resources and product pipelines. Neuraxis continues to report net losses and negative earnings per share, indicating ongoing investment and operational risks. Adoption depends on continued payer coverage, physician acceptance, and patient compliance. Clinical trials for pipeline indications carry inherent risks of inconclusive results or regulatory delays. Market penetration beyond pediatric hospitals and adult gastroenterologists may face challenges. The company’s financial position requires monitoring given its growth-stage status [S2].

Neuraxis’ competitive moat is built on its first-to-market status with PENFS technology for functional abdominal pain, a strong portfolio of device and method patents protecting its unique approach targeting cranial nerve branches in the ear, and endorsements from leading pediatric academic societies including NASPGHAN. The assignment of a Category I CPT code and a Federal Supply Schedule contract further support market access and reimbursement. The company’s focus on drug-free neuromodulation therapies addresses unmet medical needs with limited approved drug alternatives, particularly in pediatric populations. These factors collectively create barriers to entry and support differentiation in a competitive neurostimulation market [S1].

• Clinical and Regulatory Risk: Ongoing clinical trials for new indications may not yield positive results or receive timely regulatory clearance, impacting product expansion.
• Competitive Risk: Larger neurostimulation companies with more resources may develop competing technologies or capture market share.
• Financial Risk: Continued net losses and reliance on capital raises may affect liquidity and operational sustainability.
• Market Adoption Risk: Physician acceptance, payer reimbursement, and patient compliance are critical for commercial success and may vary.

• Neuraxis, Inc. is a growth-stage medical technology company focused on neuromodulation therapies for gastrointestinal (GI) disorders, specifically disorders of the gut-brain interaction (DGBIs) in pediatrics and adults [S1].
• The company has developed four FDA-cleared products: IB-Stim (a PENFS device for functional abdominal pain associated with IBS and functional dyspepsia), RED (Rectal Expulsion Device for neuromuscular function evaluation), NSS-2 Bridge (licensed and later reacquired from Masimo), and NeuroStim (electroacupuncture device reserved for research) [S1].
• IB-Stim is FDA cleared as a Class II medical device for patients 8 years and older with functional abdominal pain related to IBS and functional dyspepsia, including nausea symptoms [S1].
• IB-Stim is the only FDA-approved or cleared treatment recommended in pediatric functional abdominal pain guidelines by NASPGHAN, the leading pediatric academic society [S1].
• The company holds a Category I CPT code (64567) effective January 1, 2026, for PENFS procedures, facilitating physician reimbursement and credibility [S1].
• Neuraxis was awarded a Federal Supply Schedule contract in December 2025 to sell IB-Stim for FDA indications including functional abdominal pain with IBS and functional dyspepsia [S1].
• The company targets pediatric and adult markets with a focus on children’s hospitals and adult gastroenterologists and pain physicians, including in the Veterans Affairs system [S1].
• Neuraxis emphasizes drug-free neuromodulation therapies to reduce medication burden and improve patient outcomes in complex GI disorders [S1].
• The company’s pipeline includes ongoing clinical trials for PENFS in multiple pediatric and adult conditions such as post-concussion syndrome, cyclic vomiting syndrome, post-operative pain, and fibromyalgia pain [S1].
• Neuraxis has strong clinical data from randomized controlled trials supporting IB-Stim’s efficacy and safety, with high patient compliance and recommendation rates [S1].
• The company’s competitive strengths include first-to-market status, a strong portfolio of device and method patents, academic society guideline endorsements, and a strong pediatric pipeline [S1].
• The neurostimulation market is competitive with large established companies, but Neuraxis holds method patents protecting its approach targeting cranial nerve branches in the ear for functional bowel disorders [S1].
• The company’s list price for IB-Stim is $1,195 per device and $4,780 per patient, with a strong gross margin and direct sales force [S1].
• Financial snapshot as of 2026-09-30 shows cash and equivalents of $4.48 million, current assets of $6.05 million, current liabilities of $2.89 million, resulting in a current ratio of 2.1 and cash ratio of 1.55 [S2].
• For the nine months ended 2026-09-30, Neuraxis reported a net loss of $6.55 million and basic and diluted EPS of -$0.52 [S2].
• Revenue for the fiscal year ended 2025-12-31 was approximately $3.57 million [S2].
• Recent news highlights include record Q2 2026 results driven by PENFS growth, expanded insurance coverage for IB-Stim therapy, inclusion of PENFS technology in pediatric gastroenterology guidelines, and expansion of PENFS coverage by 18 million lives [N2][N4][N6].
• The company’s stock has experienced significant gains over the past year, reflecting market interest in its growth and product adoption [N2].
• Neuraxis completed a $5 million registered direct offering in May 2025 to support growth of IB-Stim therapy [N2].
• The company terminated the NSS-2 Bridge license with Masimo in July 2025, regaining rights to related trademarks and patents [S1].